Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting.
BACKGROUND
Magnetic resonance imaging (MRI) is the best biomarker of inflammatory disease activity in relapsing remitting Multiple Sclerosis (RRMS) so far but the association with disability is weak. Appearance of new MRI-lesions is used to evaluate response to immunotherapies in individual patients as well as being the most common primary outcome in phase-2 trials. Measurements of brain atrophy show promising outcomes in natural cohort studies and some phase-2 trials. From a theoretical perspective they might represent irreversible neurodegeneration and be more closely associated with disability. However, these atrophy measurements are not yet established as prognostic factors in real-life clinical routine. High field MRI has improved image quality and resolution and new methods to measure atrophy dynamics have become available.


OBJECTIVE
To investigate the predictive value of MRI classification criteria in to high/low atrophy and inflammation groups, and to explore predictive capacity of two consecutive routine MRI scans for disability progression in RRMS in a real-life prospective cohort.


METHODS
82 RRMS-patients (40 untreated, 42 treated with immunotherapies, mean age 40 years, median Expanded Disability Status Scale (EDSS) of 2, underwent two clinically indicated MRI scans (3 Tesla) within 5-14 months, and EDSS assessment after a mean of 3.0 (1.5-4.2) years. We investigated the predictive value of predefined classifications in low/high inflammatory and atrophy groups for EDSS progression (≥1.5 if baseline EDSS = 0, ≥1.0 if baseline EDSS <5, ≥0.5 for other) by chi-square tests and by analysis of variance (ANOVA). The classifications were based on current scientific or clinical recommendation (e.g., treatment response criteria). Brain atrophy was assessed with three different methods (SIENA, SIENAX, and FreeSurfer). Post-hoc analyses aimed to explore clinical data and dynamics of MRI outcomes as predictors in multivariate linear and logit models.


RESULTS
Progression was observed in 24% of patients and was independent from treatment status. None of the predefined classifications were predictive for progression. Explorative post-hoc analyses found lower baseline EDSS and higher grey matter atrophy (FreeSurfer) as best predictors (R (2) = 0.29) for EDSS progression and the accuracy was overall good (Area under the curve = 0.81).


CONCLUSIONS
Beside EDSS at baseline, short-term grey matter atrophy is predictive for EDSS progression in treated and untreated RRMS. The development of atrophy measurements for individual risk counselling and evaluation of treatment response seems possible, but needs further validation in larger cohorts. MRI-atrophy estimates from the FreeSurfer toolbox seem to be more reliable than older methods.
Institute of Neuroimmunology and MS (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.|Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Johanna
J
von Gumberz
Institute of Neuroimmunology and MS (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.|Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mina
M
Mahmoudi
Institute of Neuroimmunology and MS (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.|Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Kim
K
Young
Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital Zürich, Zürich, Switzerland.
Sven
S
Schippling
Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital Zürich, Zürich, Switzerland.
Roland
R
Martin
Institute of Neuroimmunology and MS (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.|Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christoph
C
Heesen
Institute of Neuroimmunology and MS (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.|Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Susanne
S
Siemonsen
Institute of Neuroimmunology and MS (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.|Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jan-Patrick
JP
Stellmann
Atrophy; Disability progression; Lesions; MRI; Multiple sclerosis; Predictors
Stat Methods Med Res. 2015 Feb;24(1):68-106
24919829
Mult Scler. 2016 Nov;22(13):1709-1718
26883943
J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1082-91
23524331
Neuroimage. 2004;23 Suppl 1:S208-19
15501092
Nat Rev Neurol. 2014 Apr;10(4):225-38
24638138
Brain. 2010 Jul;133(Pt 7):1914-29
20534650
Nat Rev Neurol. 2009 Dec;5(12):672-82
19953117
Neurology. 2013 Nov 12;81(20):1759-67
24122185
Ann Neurol. 2011 Feb;69(2):292-302
21387374
Brain. 2016 Jan;139(Pt 1):115-26
26637488
Nat Rev Neurol. 2013 Sep;9(9):504-12
23897407
PLoS One. 2015 Feb 06;10 (2):e0116559
25659100
Ann Neurol. 2009 Mar;65(3):268-75
19334061
Brain. 2008 Mar;131(Pt 3):808-17
18234696
J Neurol Sci. 2013 Aug 15;331(1-2):10-3
23692966
Annu Rev Public Health. 1997;18:83-104
9143713
Neurology. 2005 Oct 11;65(7):1071-6
16217061
Neuroimage. 2012 Aug 15;62(2):774-81
22248573
JAMA Neurol. 2013 May;70(5):556-64
23460023
Mult Scler. 2008 May;14(4):479-84
18562504
Ann Neurol. 2013 Sep;74(3):317-27
23955638
AJNR Am J Neuroradiol. 2015 Mar;36(3):425-31
24831592
Neurology. 2009 Feb 24;72(8):705-11
19073945
J Neuroimaging. 2004 Jul;14(3 Suppl):36S-45S
15228758
Neurol Neuroimmunol Neuroinflamm. 2015 Jul 02;2(4):e132
26185778
Neurology. 1983 Nov;33(11):1444-52
6685237
J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1109-15
24554101
Neuroimage. 2002 Sep;17(1):479-89
12482100
Brain. 2015 Jul;138(Pt 7):1863-74
25902415
Eur J Neurol. 2015 Jul;22(7):1113-23
25904020
Neurology. 2008 Aug 26;71(9):624-31
18480462
Neuroimage. 2012 Jul 16;61(4):1402-18
22430496